Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts

Abstract

Viral replication usually requires that innate intracellular lines of defence be overcome, a task usually accomplished by specialized viral gene products. The virion infectivity factor (Vif) protein of human immunodeficiency virus (HIV) is required during the late stages of viral production to counter the antiviral activity of APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G; also known as CEM15), a protein expressed notably in human T lymphocytes1,2,3,4. When produced in the presence of APOBEC3G, vif-defective virus is non-infectious. APOBEC3G is closely related to APOBEC1, the central component of an RNA-editing complex that deaminates a cytosine residue in apoB messenger RNA5,6,7. APOBEC family members also have potent DNA mutator activity through dC deamination8; however, whether the editing potential of APOBEC3G has any relevance to HIV inhibition is unknown. Here, we demonstrate that it does, as APOBEC3G exerts its antiviral effect during reverse transcription to trigger G-to-A hypermutation in the nascent retroviral DNA. We also find that APOBEC3G can act on a broad range of retroviruses in addition to HIV, suggesting that hypermutation by editing is a general innate defence mechanism against this important group of pathogens.

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: The putative catalytic site of APOBEC3G is important for HIV inhibition.
Figure 2: APOBEC3G is a broadly active antiretroviral.
Figure 3: Decreased viral DNA yields do not fully account for APOBEC3G-mediated inhibition.
Figure 4: APOBEC3G triggers G-to-A hypermutation in the retroviral DNA.

References

  1. von Schwedler, U., Song, J., Aiken, C. & Trono, D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67, 4945–4955 (1993)

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Gabuzda, D. H. et al. Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J. Virol. 66, 6489–6495 (1992)

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Simon, J. H. & Malim, M. H. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J. Virol. 70, 5297–5305 (1996)

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646–650 (2002)

    ADS  CAS  Article  PubMed  Google Scholar 

  5. Jarmuz, A. et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285–296 (2002)

    CAS  Article  PubMed  Google Scholar 

  6. Powell, L. M. et al. A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine. Cell 50, 831–840 (1987)

    CAS  Article  PubMed  Google Scholar 

  7. Teng, B., Burant, C. F. & Davidson, N. O. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 260, 1816–1819 (1993)

    ADS  CAS  Article  PubMed  Google Scholar 

  8. Harris, R. S., Petersen-Mahrt, S. K. & Neuberger, M. S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 10, 1247–1253 (2002)

    CAS  Article  PubMed  Google Scholar 

  9. MacGinnitie, A. J., Anant, S. & Davidson, N. O. Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity. J. Biol. Chem. 270, 14768–14775 (1995)

    CAS  Article  PubMed  Google Scholar 

  10. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L. & Trono, D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nature Biotechnol. 15, 871–875 (1997)

    CAS  Article  Google Scholar 

  11. Kotsopoulou, E., Kim, V. N., Kingsman, A. J., Kingsman, S. M. & Mitrophanous, K. A. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J. Virol. 74, 4839–4852 (2000)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. Negre, D. et al. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther. 7, 1613–1623 (2000)

    CAS  Article  PubMed  Google Scholar 

  13. Mitrophanous, K. et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther. 6, 1808–1818 (1999)

    CAS  Article  PubMed  Google Scholar 

  14. Charneau, P. et al. HIV-1 reverse transcription. A termination step at the center of the genome. J. Mol. Biol. 241, 651–662 (1994)

    CAS  Article  PubMed  Google Scholar 

  15. Jayanta, C., Ming, T., Chan, K., Eric, P. & Alt, F. W. Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 422, 726–730 (2003)

    Article  Google Scholar 

  16. Klarmann, G. J., Chen, X., North, T. W. & Preston, B. D. Incorporation of uracil into minus strand DNA affects the specificity of plus strand synthesis initiation during lentiviral reverse transcription. J. Biol. Chem. 278, 7902–7909 (2003)

    CAS  Article  PubMed  Google Scholar 

  17. Borman, A. M., Quillent, C., Charneau, P., Kean, K. M. & Clavel, F. A highly defective HIV-1 group O provirus: evidence for the role of local sequence determinants in G → A hypermutation during negative-strand viral DNA synthesis. Virology 208, 601–609 (1995)

    CAS  Article  PubMed  Google Scholar 

  18. Vartanian, J. P., Meyerhans, A., Asjo, B. & Wain-Hobson, S. Selection, recombination, and G → A hypermutation of human immunodeficiency virus type 1 genomes. J. Virol. 65, 1779–1788 (1991)

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Wain-Hobson, S., Sonigo, P., Guyader, M., Gazit, A. & Henry, M. Erratic G → A hypermutation within a complete caprine arthritis-encephalitis virus (CAEV) provirus. Virology 209, 297–303 (1995)

    CAS  Article  PubMed  Google Scholar 

  20. Johnson, P. R., Hamm, T. E., Goldstein, S., Kitov, S. & Hirsch, V. M. The genetic fate of molecularly cloned simian immunodeficiency virus in experimentally infected macaques. Virology 185, 217–228 (1991)

    CAS  Article  PubMed  Google Scholar 

  21. Turelli, P., Guiguen, F., Mornex, J. F., Vigne, R. & Querat, G. dUTPase-minus caprine arthritis-encephalitis virus is attenuated for pathogenesis and accumulates G-to-A substitutions. J. Virol. 71, 4522–4530 (1997)

    CAS  PubMed  PubMed Central  Google Scholar 

  22. Mansky, L. M. In vivo analysis of human T-cell leukemia virus type 1 reverse transcription accuracy. J. Virol. 74, 9525–9531 (2000)

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  23. Pathak, V. K. & Temin, H. M. Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations. Proc. Natl Acad. Sci. USA 87, 6019–6023 (1990)

    ADS  CAS  Article  PubMed  PubMed Central  Google Scholar 

  24. Gunther, S. et al. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G → A hypermutation. Virology 235, 104–108 (1997)

    CAS  Article  PubMed  Google Scholar 

  25. Turelli, P. et al. Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication. Mol. Cell 7, 1245–2154 (2001)

    CAS  Article  PubMed  Google Scholar 

  26. Dettenhofer, M. & Yu, X. F. Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J. Virol. 73, 1460–1467 (1999)

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Butler, S. L., Hansen, M. S. & Bushman, F. D. A quantitative assay for HIV DNA integration in vivo. Nature Med. 7, 631–634 (2001)

    CAS  Article  PubMed  Google Scholar 

  28. Yerly, S. et al. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354, 729–733 (1999)

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

We thank S. Vianin for technical assistance, and M. Malim, R. Mulligan, K. Mitrophanous, F.-L. Cosset and M. Matsuda for the gift of reagents. This work was supported by the Swiss National Science Foundation.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Didier Trono.

Ethics declarations

Competing interests

The authors declare that they have no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mangeat, B., Turelli, P., Caron, G. et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424, 99–103 (2003). https://doi.org/10.1038/nature01709

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature01709

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing